Gene regulation and signalling

GENE REGULATION, STEM CELLS AND CANCER

GROUP LEADER:
Susana de la Luna (ICREA Research Professor)

POSTDOCTORAL FELLOWS:
Chiara Di Vona, Julia Rowenstrunk

PhD STUDENTS:
Borja Balbastre (since October), Laura Barba, Jacopo Boni, Rianne Cort

LAB TECHNICIANS:
Krisztina Arato, Alicia Raya

Summary

DYRK (dual-specificity tyrosine-regulated kinases) family members are found in four of the five main taxa (Animalia, plantae, fungi and Protista), and all them share common structural and biochemical properties. The mammalian DYRKs participate in signalling pathways critical for developmental processes and cell homeostasis, and their dysregulation has been linked to disease in humans. In the case of DYRK1A, both its overexpression, as part of the Down syndrome critical region, as well as its haploinsufficiency are linked to clinical phenotypes in humans. Our group is interested in understanding the biological roles of DYRK kinases, how they are regulated and which are the mechanisms underlying their connection to disease.

Progress during 2017 has focused mostly on DYRK1A. The biochemical analysis of DYRK1A missense mutants identified in patients with DYRK1A haploinsufficiency syndrome have shown that most of them, but not all, are loss of function mutations. In addition, we have associated a novel biological role to DYRK1A as a critical regulator of VEGF/calcium/NFAT signalling in angiogenesis.

Research Projects

  • Identification of regulatory mechanisms for DYRK kinases activity: allosteric regulation, protein stability, expression.
  • Characterization of the molecular mechanism that underlies the activity of DYRK class I as transcriptional regulators.
  • Definition of the interactome of class I DYRKs.
  • Role of DYRKs as regulators of the activity of the NFAT transcription factors in calcineurin-dependent signalling pathways.
  • Characterization of DYRK1A missense mutations in DYRK1A haploinsufficiency syndrome
  • Exploring DYRKs as potential targets in cancer.